Weight-loss drugs like Wegovy and Zepbound often cause nausea and other side effects. Brain scientists are looking for ways ...

GLP-1 RAs, particularly semaglutide and tirzepatide, outperform older medications in achieving significant weight loss in adults with and without type 2 diabetes. Semaglutide and tirzepatide met ...

Detailed price information for American Express Company (AXP-N) from The Globe and Mail including charting and trades.

ObesityWeek 2025, held in Atlanta from November 4-7, showcased unprecedented clinical data that signals a fundamental shift in the obesity treatment landscape. The most striking breakthrough at ...

Novo Nordisk remains a dominant business with a strong pipeline, and current multiples are low enough to justify a buy. Read my latest analysis of NVO stock.

Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and ...

Eli Lilly (LLY) stock is trading at record highs after the pharmaceutical company reached a deal with the White House to ...

Prescriptions for GLP-1 receptor agonists in cancer patients have increased despite lack of clinical guidance. The overall ...

Makers of weight-loss drugs saw their stocks surge in 2024, but no more. Now Trump's price deal adds new questions. Is the ...

BARCELONA (AP) — Real Madrid buscará recuperarse de la derrota sufrida esta semana en Liverpool, cuando atraviese la capital española para jugar contra el Rayo Vallecano en un encuentro dominical de ...

NBC News' Tom Llamas talks to CEO of Eli Lilly David Ricks about the company's new deal with the Trump administration to cut down some of the cost of their weight loss drug Zepbound.

WASHINGTON (AP) — President Donald Trump unveiled a deal Thursday with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for the popular obesity treatments Zepbound and Wegovy ...